Romosozumab, used in osteoporosis treatment, may offer dual benefits by also reducing the risk for osteoarthritis, notably knee osteoarthritis.

A sedentary lifestyle, rising obesity levels, increased participation in sports, and inflammatory disorders are believed to ...

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access ...

Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release. The agreement adds Zilretta, an injectable osteoarthritis treatment, to ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

Individuals with vs without knee, hip, or hand OA were associated with a significantly increased risk for sleep apnea.

First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synov ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

The device has already completed a 12-week trial with a small group of users, who wore it for up to an hour a day, five to seven days a week.

Higher UPF-consumption was linked to worse knee OA outcomes among women, including higher pain scores, worse physical function, and thinner knee cartilage.